神經病學領域小分子原料藥市場規模、佔有率和成長分析：按治療適應症、生產形式、原料藥類別、最終用戶和地區分類－2026-2033年產業預測

2024 年全球神經病學領域小分子 API 市場價值為 180 億美元，預計從 2025 年的 192.6 億美元成長到 2033 年的 330.9 億美元，預測期（2026-2033 年）複合年成長率為 7.0%。

全球神經病學領域的小分子原料藥市場主要針對生產中樞神經系統 (CNS) 疾病治療所需關鍵活性成分的製造商，這些疾病包括阿茲海默症、帕金森氏症、癲癇和多發性硬化症。市場需求主要受人口結構變化和神經退化性疾病盛行率上升的驅動，導致人們對價格合理的治療治療方法的需求日益成長。該市場正從生產基礎學名藥向生產複雜的標靶小分子化合物轉型，並透過垂直整合和專業化提高效率。關鍵成長要素包括藥物化學和中樞神經系統藥物傳遞技術的進步，使得設計能夠有效穿過血腦障壁的分子成為可能。此外，人工智慧技術透過最佳化工作流程和加速候選化合物的篩選，簡化了藥物發現過程，從而提高了小分子原料藥在神經病學領域的吸引力，並促進了研發人員和製造商之間的合作。

神經系統小分子原料藥市場的全球促進因素

神經系統疾病發生率的不斷上升顯著推動了對有效治療方法的需求，進而推動了針對中樞神經系統的小分子藥物原料藥）的研發和生產投資。這種日益成長的臨床需求促使製藥公司優先開發可口服給藥且能最佳化穿過血腦障壁的小分子平台。因此，拓展專業合成和製劑能力變得愈發重要。此外，不斷增加的研發管線活動和策略聯盟正在加強生產能力，從而持續推動市場對高品質神經系統小分子API的需求。

全球神經系統小分子原料藥市場面臨的限制因素

由於中樞神經系統治療藥物的監管要求嚴格而複雜，全球小分子神經系統原料藥（API）市場面臨許多阻礙。這些監管規定對小分子原料藥的研發和商業化構成重大障礙，最終阻礙了市場成長。全面的安全性數據、雜質評估和詳細資訊要求進一步加劇了生產商面臨的挑戰。此外，監管機構通常對神經活性化合物持謹慎態度，導致研發過程更加複雜，合規要求也更高。這需要專門的設施和完善的品管體系，增加了營運負擔，並加劇了投資者和開發商的風險意識，這可能會阻礙投資並延遲新產品的上市。

神經學領域小分子原料藥全球市場趨勢

全球神經病學小分子原料藥市場正顯著轉向高度標靶治療，這主要得益於人們對神經系統疾病機制認知的不斷加深。這一趨勢強調開發能夠精準調控神經通路並增強治療特異性的小分子原料藥。隨著產業日益關注轉化檢驗和腦滲透性分析，候選化合物的篩選效率不斷提高，風險降低策略得到加強，臨床醫生、化學家和轉化科學家之間的合作日益密切。製造商正在調整生產流程以滿足療效和選擇性的要求，建構差異化的產品特性以加速臨床評估和商業化，並在產品設計中越來越重視以患者為中心的終點指標。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

神經病學領域小分子原料藥的全球市場規模：依治療適應症分類。

• 神經退化性疾病
• 癲癇和癲癇發作
• 多發性硬化症（MS）
• 憂鬱症與焦慮症

神經病學領域小分子原料藥的全球市場規模：依生產類型分類

• 內部生產
• 外包

全球神經學領域小分子原料藥市場規模：依原料藥類別分類

• 通用小分子非專利藥
• 創新取得專利的API

神經學領域小分子原料藥的全球市場規模：依最終用戶分類

• 製藥公司
• 學術研究機構

全球神經學領域小分子原料藥市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要企業2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要企業的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要企業簡介

• Amgen Inc.
• Sigma-Aldrich
• Merck KGaA
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Pfizer Inc.
• Johnson & Johnson
• Roche Holding AG
• Biogen Inc.
• Gedeon Richter Plc
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma Ltd.
• H. Lundbeck A/S
• Eli Lilly and Company
• Bayer AG
• Ipsen SA
• Acadia Pharmaceuticals Inc.
• Mallinckrodt Pharmaceuticals
• Alkermes plc

結論與建議

Global Neurology Small Molecule Api Market size was valued at USD 18.0 Billion in 2024 and is poised to grow from USD 19.26 Billion in 2025 to USD 33.09 Billion by 2033, growing at a CAGR of 7.0% during the forecast period (2026-2033).

The global neurology small molecule API market encompasses manufacturers producing essential active pharmaceutical ingredients for therapies addressing central nervous system disorders, crucial for treating conditions like Alzheimer's, Parkinson's, epilepsy, and multiple sclerosis. Demand is primarily driven by demographic shifts and a rising incidence of neurodegenerative diseases, prompting the need for affordable treatment options. The market has evolved from basic generic production toward complex, targeted small molecules, with vertical integration and specialization enhancing efficiency. Key growth factors include advancements in medicinal chemistry and CNS drug delivery, enabling the design of molecules that effectively penetrate the blood-brain barrier. Furthermore, AI technologies are streamlining drug discovery by optimizing workflows and accelerating candidate identification, ultimately enhancing the attractiveness of neurology small molecule APIs and fostering partnerships between developers and manufacturers.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neurology Small Molecule Api market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neurology Small Molecule Api Market Segments Analysis

Global neurology small molecule api market is segmented by therapeutic indication, manufacturing type, api category, end-user and region. Based on therapeutic indication, the market is segmented into Neurodegenerative Diseases, Epilepsy & Seizure Disorders, Multiple Sclerosis (MS) and Depression & Anxiety Disorders. Based on manufacturing type, the market is segmented into In-house Manufacturing and Outsourced. Based on api category, the market is segmented into Generic Small Molecule APIs and Innovative/Patented APIs. Based on end-user, the market is segmented into Pharmaceutical Companies and Academic & Research Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neurology Small Molecule Api Market

The rising incidence of neurological disorders is significantly boosting the demand for effective therapies, which drives investments in the discovery and production of small molecule active pharmaceutical ingredients aimed at central nervous system targets. This heightened clinical need compels pharmaceutical companies to prioritize small molecule platforms that can be tailored for oral administration and optimized for traversing the blood-brain barrier. As a result, there is an increased emphasis on scaling up specialized synthesis and formulation capabilities. Furthermore, heightened pipeline activity and strategic alliances are reinforcing manufacturing commitments, thereby fostering a continuous market demand for high-quality neurology small molecule APIs.

Restraints in the Global Neurology Small Molecule Api Market

The Global Neurology Small Molecule API market faces significant constraints due to stringent and intricate regulatory requirements governing central nervous system therapeutics. These guidelines establish substantial barriers to the development and commercialization of small molecule APIs, ultimately hindering market growth. The necessity for comprehensive safety data, impurity assessments, and formulation details compounds the challenges faced by manufacturers. Furthermore, regulatory bodies typically exercise caution regarding neuroactive compounds, leading to more complex development processes and increased compliance demands. This results in a need for specialized facilities and robust quality management systems, imposing a greater operational burden and instilling a sense of risk among investors and developers, which can impede investments and delay the entry of new products into the market.

Market Trends of the Global Neurology Small Molecule Api Market

The Global Neurology Small Molecule API market is experiencing a significant shift towards advanced targeted therapies, fueled by an enhanced understanding of neurological disease mechanisms. This trend emphasizes the development of small molecule APIs that offer precise modulation of neuronal pathways and improved therapeutic specificity. As the industry focuses on translational validation and brain penetration profiling, candidate selection becomes more efficient and risk reduction strategies are strengthened, fostering collaboration among clinicians, chemists, and translational scientists. Manufacturers are adapting their processes to meet potency and selectivity demands, creating differentiated product profiles that expedite clinical evaluation and commercialization while increasingly prioritizing patient-centric endpoints in their designs.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Neurology Small Molecule API Market Size by Therapeutic Indication & CAGR (2026-2033)

• Market Overview
• Neurodegenerative Diseases
• Epilepsy & Seizure Disorders
• Multiple Sclerosis (MS)
• Depression & Anxiety Disorders

Global Neurology Small Molecule API Market Size by Manufacturing Type & CAGR (2026-2033)

• Market Overview
• In-house Manufacturing
• Outsourced

Global Neurology Small Molecule API Market Size by API Category & CAGR (2026-2033)

• Market Overview
• Generic Small Molecule APIs
• Innovative/Patented APIs

Global Neurology Small Molecule API Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical Companies
• Academic & Research Institutes

Global Neurology Small Molecule API Market Size & CAGR (2026-2033)

• North America (Therapeutic Indication, Manufacturing Type, API Category, End-User)
  • US
  • Canada
• Europe (Therapeutic Indication, Manufacturing Type, API Category, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapeutic Indication, Manufacturing Type, API Category, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapeutic Indication, Manufacturing Type, API Category, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapeutic Indication, Manufacturing Type, API Category, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sigma-Aldrich
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gedeon Richter Plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkermes plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations